Abstract:
PURPOSE: This study examined the patterns and frequency of genetic changes
responsible for resistance to first-line (rifampicin and isoniazid), fluoroquinolones,
and second-line injectable drugs in drug-resistant Mycobacterium tuberculosis
(MTB) isolated from culture-positive pulmonary tuberculosis (PTB) symptomatic
attendees of spiritual holy water sites (HWSs) in the Amhara region.
PATIENTS AND METHODS: From June 2019 to March 2020, a cross-sectional study
was carried out. A total of 122 culture-positive MTB isolates from PTB-suspected
attendees of HWSs in the Amhara region were evaluated for their drug resistance
profiles, and characterized gene mutations conferring resistance to rifampicin
(RIF), isoniazid (INH), fluoroquinolones (FLQs), and second-line injectable drugs
(SLIDs) using GenoType®MTBDRplus VER2.0 and GenoType®MTBDRsl VER2.0.
Drug-resistant MTB isolates were Spoligotyped following the manufacturer’s
protocol.
RESULTS: Genetic changes (mutations) responsible for resistance to RIF, INH,
and FLQs were identified in 15/122 (12.3%), 20/122 (16.4%), and 5/20 (25%) of
MTB isolates, respectively. In RIF-resistant, rpoB/Ser531Lue (n = 12, 80%) was
most frequent followed by His526Tyr (6.7%). Amongst INH-resistant isolates,
katG/Ser315Thr1 (n = 19, 95%) was the most frequent. Of 15 MDR-TB, the
majority (n = 12, 80%) isolates had mutations at both rpoB/Ser531Leu and
katG/Ser315Thr1. All 20 INH and/or RIF-resistant isolates were tested with the
MTBDRsl VER 2.0, yielding 5 FLQs-resistant isolates with gene mutations at rpoB/
Ser531Lue, katG/Ser315Thr1, and gyrA/Asp94Ala genes. Of 20 Spoligotyped
drug-resistant MTB isolates, the majority (n = 11, 55%) and 6 (30%) were SIT149/
T3-ETH and SIT21/CAS1-Kili sublineages, respectively; and they were any INHresistant (mono-hetero/multi-). Of 15 RIF-resistant (RR/MDR-TB) isolates, 7
were SIT149/T3-ETH, while 6 were SIT21/CAS1-Kili sublineages. FLQ resistance
was detected in four SIT21/CAS1-Kili lineages.
CONCLUSION: In the current study, the most common gene mutations responsible
for resistance to INH, RIF, and FLQs were identified. SIT149/T3-ETH and SIT21/CAS1-Kili constitute the majority of drug-resistant TB (DR-TB) isolates. To further
understand the complete spectrum of genetic changes/mutations and related
genotypes, a sequencing technology is warranted.